Thymosin Alpha-1 for Dogs
Thymosin alpha-1 (TA1)
The short answer
Thymosin alpha-1 has the most established safety profile of anything covered here, having been approved for human use outside the United States for decades with no cumulative toxicity reported. It is also notable as an exception to the cancer contraindication that applies to most growth-promoting peptides — published data suggests it may support immune surveillance without appearing to promote tumour growth. The honest limitation is that essentially all of that evidence is human; no canine clinical trials exist.
What it is and how it is thought to work
Thymosin alpha-1 is a peptide the thymus gland produces naturally to help train the immune system. Rather than pushing immune activity up or damping it down, research describes it rebalancing immune function — which is why it is studied both in immune-deficient patients and as an adjunct in cancer care.
Mechanism in clinical terms
Reported to bind TLR2 and TLR9, activating natural killer cells, CD4+ and CD8+ T-cell populations, and IFN-gamma / IL-2 production. Immunomodulatory rather than immunostimulant. Investigated as an oncology adjunct, with PTEN/PI3K/Akt/mTOR pathway modulation observed in vitro.
Canine dosing by weight class
Figures below are reported as they appear in the source literature. They are not recommendations, and dosing for an individual dog must be set by a veterinarian.
Small / toy breed
under 22 lb (10 kg)
- Reported dose
- 100–1,000 mcg per dose
- Frequency
- 2-3x weekly
- Duration
- 4-12 weeks or ongoing
- Studied for
- Immune support, chronic infection, oncology adjunct
Medium breed
22–77 lb (10–35 kg)
- Reported dose
- 500–2,000 mcg per dose
- Frequency
- 2-3x weekly
- Duration
- 4-12 weeks or ongoing
- Studied for
- Immune support, chronic infection, oncology adjunct
Large / giant breed
over 77 lb (35 kg)
- Reported dose
- 1,750–2,000 mcg per dose
- Frequency
- 2-3x weekly
- Duration
- 4-12 weeks or ongoing
- Studied for
- Immune support, chronic infection, oncology adjunct
Need a figure for a specific weight? Use the dose calculator, or see the weight-specific pages: small / toy breed, medium breed, large / giant breed.
Contraindications and warnings
Read these before anything else on the page.
No canine-specific clinical trials
The strong evidence base for thymosin alpha-1 is human. Canine dosing is extrapolated. It is included with a good evidence grade because the safety and mechanism data are unusually solid, not because dogs have been formally studied.
Example research protocol
A representative timeline drawn from the published literature, showing what is monitored and when. Any actual protocol should be set by the veterinarian managing the case.
- 1Week 1Immune priming
What owners observe
No visible effects are expected in the first week. Some dogs are quieter on dosing days, which is transient. Track appetite and energy so you have a baseline.
Clinical monitoring
Baseline CBC with differential, and lymphocyte subsets where available. 50-100 mcg/kg subcutaneously three times weekly. TLR2/TLR9 activation is reported within 24 hours, with NK cell upregulation by days 3-5.
- 2Weeks 2-4Immune activation
What owners observe
In immune-compromised dogs, improved energy and appetite and fewer secondary infections are the signals to watch. In oncology cases, stabilisation rather than dramatic change is a meaningful result.
Clinical monitoring
IFN-gamma and IL-2 production increasing. Repeat CBC at week 4 with improved lymphocyte counts expected. Continue 2-3x weekly. Stagger injections if combining with other compounds.
- 3Weeks 4-12Sustained response
What owners observe
Quality of life is the primary endpoint. Sustained appetite, comfort, and engagement matter more than any single measurement. Report any new lumps or sudden decline promptly.
Clinical monitoring
Continue twice weekly. For oncology cases, imaging around week 8 for response assessment. Long-term continuation is plausible for chronic conditions; no cumulative toxicity has been reported.
What Thymosin Alpha-1 is investigated for
How it compares
- Thymosin Alpha-1 vs TB-500 for dogs — how Thymosin Alpha-1 differs from TB-500
Common questions
Is Thymosin Alpha-1 safe for dogs?+
Thymosin alpha-1 has the most established safety profile of anything covered here, having been approved for human use outside the United States for decades with no cumulative toxicity reported. It is also notable as an exception to the cancer contraindication that applies to most growth-promoting peptides — published data suggests it may support immune surveillance without appearing to promote tumour growth. The honest limitation is that essentially all of that evidence is human; no canine clinical trials exist.
How much Thymosin Alpha-1 should I give my dog?+
Reported doses vary by weight class. Small / toy breed (under 22 lb (10 kg)): 100–1,000 mcg per dose, 2-3x weekly. Medium breed (22–77 lb (10–35 kg)): 500–2,000 mcg per dose, 2-3x weekly. Large / giant breed (over 77 lb (35 kg)): 1,750–2,000 mcg per dose, 2-3x weekly. These figures are reported as they appear in the source literature and are not recommendations — dosing for an individual dog must be set by a veterinarian who has examined the animal.
How is Thymosin Alpha-1 given to dogs?+
Thymosin Alpha-1 is administered by subcutaneous injection. See the injection guide and reconstitution guide for handling detail.
What is the evidence for Thymosin Alpha-1 in dogs?+
Thymosin Alpha-1 is graded as good evidence on this site, drawing on 5 cited studies. Thymosin alpha-1 is a peptide the thymus gland produces naturally to help train the immune system. Rather than pushing immune activity up or damping it down, research describes it rebalancing immune function — which is why it is studied both in immune-deficient patients and as an adjunct in cancer care.
References
- 1.King R, Tuthill C Immune Modulation with Thymosin Alpha 1 Treatment. Vitamins and Hormones, 2016. PMID 27450734
- 2.Dominari A, Hathaway Iii D, Pandav K, et al. Thymosin alpha 1: A comprehensive review of the literature. World Journal of Virology, 2020. PMID 33362999
- 3.Wei Y, Zhang J, Yan X, et al. Thymosin α-1 in cancer therapy: Immunoregulation and potential applications. International Immunopharmacology, 2023. PMID 36812669
- 4.Guo Y, Chang H, Li J, et al. Thymosin alpha 1 suppresses proliferation and induces apoptosis in breast cancer cells through PTEN-mediated inhibition of PI3K/Akt/mTOR signaling pathway. Apoptosis, 2015. PMID 26002438
- 5.Wang F, Yu T, Zheng H, Lao X Thymosin Alpha1-Fc Modulates the Immune System and Down-regulates the Progression of Melanoma and Breast Cancer with a Prolonged Half-life. Scientific Reports, 2018. PMID 30120362
Educational information — not veterinary medical advice
Everything on this page is compiled from published peer-reviewed literature for educational and research purposes. It does not establish a veterinarian-client-patient relationship (VCPR) and is not a substitute for veterinary examination and diagnosis. Most compounds described here are investigational or used off-label and are not FDA-approved for these purposes in dogs. Extralabel drug use in animals requires a valid VCPR and the direct supervision of a licensed veterinarian under AMDUCA (21 U.S.C. §360b). Dosing figures are reported as they appear in the source literature and are not recommendations.